Alpha Interferon Treatment of Chronic Non-A, Non-B Hepatitis Caused by Intravenous Gammaglobulin

Abstract

Two patients with hypogammaglobulinemia and chronic active non-A, non-B hepatitis caused by intravenous gammaglobulin substitution were treated long-term with alpha-2b interferon (Introna®). Both achieved normal aminotransferase levels within 2–12 weeks after initiation of interferon therapy. One patient was rebiopsied after 6 months of therapy and showed some degree of improvement in the liver inflammatory activity. The beneficial effects warrant a randomized controlled study.